One more feather in the RVX science cap. Management almost seems to act like PAH is an after thought but it actually is a worthwhile market opportunity. Taking a quick look at industry numbers the current market is about $6.5-7B and is expected to grow by 6-7%/yr and reach $10-11B by 2027-30 (depending on the source). Another over looked opportunity is Apabetalone's potential use in Sepsis (Frontiers in Pharmacology). This market is apparently in need of more effective drugs and currently the market is roughly $3B and expected to grow to $$6-7.5B in the next 6-8 years, again depending on your source. 

It sure would be nice to see someone at RVX put on a business development hat, lay out the potential value of these opportunities for investors and then start developing some partnerships/investment to seriously pursue these opportunities. While they're at it they could identify the other 10 clinic ready compounds and lay out the opportunities for them as well. Probably wishful thinking that RVX might someday act like a business. Very frustrating!